Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.37 |
| ▸ | FEN1 | P39748 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12074163 | 0.86 | ALOX5AP (0.39) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL23829848 | 0.84 | ALDH1A1 (0.37) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL633227 | 0.82 | MEP1B (0.37) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL1994314 | 0.80 | MEP1B (0.41) | ALDH1A1HSD17B10HTR2AHTR2CHTR2B | |
| SCHEMBL1429267 | 0.80 | IDO1 (0.45) | ALDH1A1HSD17B10CYP3A4TDP1TSHR | |
| SCHEMBL14748359 | 0.80 | ALOX5AP (0.36) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL19782651 | 0.78 | TUBB4A (0.40) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL22366678 | 0.78 | HTR2C (0.37) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL1675886 | 0.78 | ALOX5AP (0.49) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 | |
| SCHEMBL25529592 | 0.78 | ALOX5AP (0.38) | ALOX5APFEN1ALDH1A1HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772176-A | Synthetic method of key drug intermediate of levofloxacin | 常州兰陵制药有限公司 | 2023-03-10 | — | — | CN | claimed |
| JP-7002783-A | — | — | None | — | — | JP | disclosed |
| JP-10087584-A | — | — | None | — | — | JP | disclosed |
| EP-3958865-B1 | 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES | BAYER AG (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025235686-A1 | FLUOROCAMPTOTHECIN COMPOUNDS, CONJUGATES, AND METHODS THEREOF | Aarvik Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-119069808-A | Overcharge-preventing electrolyte additive and application thereof in sodium ion battery | 浙江山高新能源有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2015069310-A1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| CN-102482221-A | Bicyclic and tricyclic compounds as KATII inhibitors | PFIZER | 2012-05-30 | — | — | CN | disclosed |
| EP-2440534-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| EP-0990639-B1 | PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR | IHARA CHEMICAL IND CO (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-6162944-A | Process for production of N-cyclopropylanilines and intermediates therefor | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-0990639-A1 | PROCESS FOR PRODUCING N-CYCLOPROPYLANILINES AND INTERMEDIATES USED THEREFOR | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2000-04-05 | — | — | EP | disclosed |
| JP-H1087584-A | PRODUCTION OF N-CYCLOPROPYLANILINES, AND INTERMEDIATE THEREFOR | IHARA CHEM IND CO LTD | 1998-04-07 | — | — | JP | disclosed |
| JP-H072783-A | PRODUCTION OF INTERMEDIATE FOR QUINOLINECARBOXYLIC ACID DERIVATIVE | SANKYO CO LTD | 1995-01-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | ALOX5AP 1586/4885FEN1 2294/4885ALDH1A1 3057/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | ALOX5AP 2807/4885FEN1 1873/4885ALDH1A1 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.